Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Delayed Data from NSDQ)

$4.45 USD

4.45
2,704,658

-0.03 (-0.67%)

Updated May 3, 2024 04:00 PM ET

After-Market: $4.43 -0.02 (-0.45%) 5:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

BioCryst Pharmaceuticals, Inc. [BCRX]

Reports for Purchase

Showing records 21 - 40 ( 174 total )

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 21

12/07/2020

Company Report

Pages: 7

Orladeyo Approval Paves Way for Oral HAE Therapy; PT to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 22

11/06/2020

Company Report

Pages: 6

Orladeyo Strategy In-Place Awaiting Approvals; With Broad Early Pipeline In Tow

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 23

10/01/2020

Daily Note

Pages: 4

Our Thoughts on BCX9930 Data Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 24

08/07/2020

Company Report

Pages: 6

Focus Remains on Oraldeyo Approval in 4Q20, With Underappreciated COVID-19 Play; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 25

03/06/2020

Company Report

Pages: 6

With Potential Berotralstat Approval on 2020 Horizon

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 26

01/27/2020

Daily Note

Pages: 4

BCX9930 Complement Inhibitor Program Can Provide Traction for Deeper Developmental Pipeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 27

11/07/2019

Company Report

Pages: 6

Positive 48-Week Durability From APeX-2

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 28

10/29/2019

Daily Note

Pages: 4

Positive Phase 1 BCX9930 Data Paves Way for PoC in PNH Patients; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 29

08/07/2019

Company Report

Pages: 5

NDA Is Underway While We Reframe the Commercial Potential; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 30

05/22/2019

Daily Note

Pages: 4

Our Thoughts and KOL Feedback Following the ApeX-2 Topline; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 31

05/09/2019

Company Report

Pages: 7

KOL Feedback Previews the Upcoming ApeX-2 Data in HAE; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 32

03/05/2019

Company Report

Pages: 6

Underappreciated Discovery Platform Continues to Prove Fruitful While HAE Timelines Remain In-tact

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 33

02/26/2019

Daily Note

Pages: 4

Oral Treatment for Acute HAE Attacks Is Ready for Phase 3

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 34

11/07/2018

Company Report

Pages: 6

Continue to Be Constructive Ahead of 2019 Clinical Catalysts; Reit Buy and $13PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 35

09/05/2018

Daily Note

Pages: 3

We Find Zenith Results Satisfying; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 36

09/05/2018

Company Report

Pages: 4

We Find Zenith Results Satisfying; Reit Buy and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 37

08/13/2018

Company Report

Pages: 11

Gleaning Information From Proxy Statement; Reit Buy and Raising PT to $13

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 38

05/09/2018

Company Report

Pages: 5

Business as Usual as the HAE Pipeline Continues to Progress

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 39

02/28/2018

Company Report

Pages: 5

Thinking Through Discovery Effort Synergies; Reit Buy and $10 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: BioCryst Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 40

01/23/2018

Daily Note

Pages: 4

NewCo Combines HAE Commercial - Deal-Making Expertise With Core Competency in Structure-Based Drug Design

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party